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Abstract
Have you ever sought to use metagenomic DNA sequences reported in scientific publica-
tions? Were you successful? Here, we reveal that metagenomes from no fewer than 20% of
the papers found in our literature search, published between 2016 and 2019, were not
deposited in a repository or were simply inaccessible. The proportion of inaccessible data
within the literature has been increasing year-on-year. Noncompliance with Open Data is
best predicted by the scientific discipline of the journal. The number of citations, journal type
(e.g., Open Access or subscription journals), and publisher are not good predictors of data
accessibility. However, many publications in high–impact factor journals do display a higher
likelihood of accessible metagenomic data sets. Twenty-first century science demands
compliance with the ethical standard of data sharing of metagenomes and DNA sequence
data more broadly. Data accessibility must become one of the routine and mandatory com-
ponents of manuscript submissions—a requirement that should be applicable across the
increasing number of disciplines using metagenomics. Compliance must be ensured and
reinforced by funders, publishers, editors, reviewers, and, ultimately, the authors.
Drivers of open data
Science, as an ‘institution of organised criticism’ [1], progresses through the act of building on
communal knowledge by ‘standing on the shoulders of giants’. Information sharing has been
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the pillar of scientific advancement ever since the first scientific journal, Philosophical Transac-
tions of the Royal Society, in 1666. Open Data is the engine of science. High-throughput DNA
sequence outputs are a relatively new form of data that offers exciting opportunities for
hypothesis testing and retesting. Such data can best serve science if they adhere to 3 principles:
transparency, reproducibility, and reusability [2]. GenBank of the National Center for Biotech-
nology Information (NCBI), Metagenomic Rapid Annotations using Subsystems Technology
(MG-RAST), the European Nucleotide Archive (ENA), and the DNA Data Bank of Japan
(DDBJ) are just a few examples of online repositories of DNA sequences. Several scientific
achievements in recent years have relied on publicly available DNA data sets (reviewed by [3]),
including assembled genomes from uncultured organisms [4], the discovery of the CRISPR-
Cas systems [5], and unravelling the relationship between microbiomes or genetic features and
specific diseases [6].
The benefits of Open Data to science are clear. It is proposed by many governments that
the publishing of government-funded research data in a transparent, reproducible, and reus-
able format can ‘strengthen citizen engagement and yield new innovative businesses’ [7]. ‘Data
can also be used in innovative ways that bring economic benefits to citizens and businesses by
releasing untapped enterprise and entrepreneurship’ [8]. The leveraging of influenza virus
(RNA) sequences [9] for the development of novel, more efficacious influenza vaccines [8]
stands as one of a handful of clear-cut examples of the potential societal and economic benefits
from Open Data. The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) also clearly demonstrates the synergy that can come from ensuring Open
Access to sequencing data—bringing rapid insights that can stem the spread of a potentially
pandemic virus in real time [10,11].
Current state of data availability
We screened all studies containing primary metagenomic data accessible through Clarivate
Web of Science from the beginning of 2016 to March 2019 (see S1 Text) to quantify the current
state of open science in studies that generate metagenomic data. We focused on metagenomic
data such as shotgun metagenomics because they represent a rich and rapidly growing data set
that can be very easily and fruitfully remined and repurposed for a wide range of hypothesis
testing.
Of the 1,269 publications we considered, 262 (20.6%) did not provide public access, either
by not mentioning data availability (12.9%) or by reporting nonexistent or empty accession
numbers (7.7%; Fig 1A). Conversely, 990 publications (78.0%) reported accession numbers or
a link to the data. Five (0.4%) studies deposited sensitive data that require authorised access,
and twelve (1%) stated that data are available from the authors upon request. Among the stud-
ies that offered no public access to data, only eight represented naïve mistakes, e.g., by errone-
ously reporting the metagenome submission code (SUB) that NCBI provides upon
submission, which cannot be used to retrieve the data set, or with typos in the code preventing
data accessibility.
Data set accessibility was significantly different across journals (generalised linear model
[GLM], binomial: likelihood ratio chi-squared test [LR Chisq]58 = 266.9, p< 0.0001; S1 Data)
and continued to decline with each passing year (LR Chisq1 = 4.9, p = 0.026). The proportion
of unavailable published metagenomes increased (GLM, binomial: LR Chisq1 = 7.5, p = 0.006;
S1 Fig) annually by 2% from 17% in 2016 (55 out of 316), 19% in 2017 (69 out of 367), and
21% in 2018 (87 out of 414). This trend continues into 2019 (up to March; 29%, or 49 out of
172). Accessibility of data was not correlated with the number of citations (time-regressed
residual values S1 Fig) (LR Chisq1 = 3.8, p = 0.060).
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Searching for correlates at the journal level, differences between disciplines—as defined by
Clarivate Analytics (generalised linear mixed effects model [GLMEM], binomial: LR Chisq10 =
23.3, p = 0.0097)—were significant (S2 Fig). To better define the distribution of unavailable
data across scientific disciplines, we assembled journals into 3 major categories (biological,
multidisciplinary, and technological/applied sciences; see S1 Text, S2 Data). Data accessibility
was significantly better for biological journals (with 13% of unavailable metagenomic data)
and the multidisciplinary journals (10%) than for technological/applied sciences (43%) (Fig
1B) (GLM, binomial: LR Chisq1 = 5.9, p = 0.015; Fig 1C). We hypothesise that an increase in
the proportion of technological/applied science papers using metagenomics can account for
the overall temporal increase in noncompliance over time.
Overall, the proportion of papers with available metagenomes was significantly different
between biological, multidisciplinary, and technological/applied science journals, regardless of
Open Access, the age of the journal, and the publisher (Table 1). Regarding publishers, none of
the publishing companies with at least 2 journals managed to achieve full compliance with data
accessibilities (S1 Data), and the differences between publishers are only marginally significant
(p = 0.0447; S3 Fig). This can be considered as a consequence of the huge difference in the data
available between journals from the same publisher. For example, in the Nature Publishing
Group, all journals share the same policies on data availability (https://www.nature.com/nature-
research/editorial-policies/reporting-standards). Submission of metagenomic raw data to a
community-endorsed, public repository is mandatory. Studies in the Nature Publishing Group
journals Nature and Nature Microbiology all complied with Open Data, while others, such as
Scientific Reports, revealed missing data for over 35% of the articles queried in this study.
Analysis of the impact factor reveals that the journals with the highest impact factor
(Table 1 and S3 Fig) fully comply with data accessibility for metagenomes (e.g., Nature, Nature
Microbiology, and Science). Journals publishing higher numbers of papers per year had a lower
proportion of accessible data (S3 Fig and Table 1), with some exceptions: Nature, Science, Peer
J (100% compliance), and Nature Communications (97%). Six ‘high volume’ journals correctly
provided access to raw data for only 25%–50% of their published articles containing metage-
nomic data (S1 Data and S4 Fig).
Fig 1. Main trends in accessibility of metagenomic data. (A) Proportion of papers with accessible metagenomic data and type of inaccessible data
(grey) (B) in B, M, or T journals. (C) Temporal trends divided by B, M, and T journals. B, biological; M, multidisciplinary; T, technological.
https://doi.org/10.1371/journal.pbio.3000698.g001
Table 1. Potential drivers of the proportion of papers with accessible data for each journal.
Driver LR Chisq df p Effect
B-M-T 16.9 2 0.0002 -
Number of papers 10.8 1 0.0010 Negative
Impact factor 7.1 1 0.0075 Positive
Publisher 24.1 14 0.0447 -
Open Access 2.6 1 0.1094 -
Age 0.4 1 0.8378 Negative
Data are accounting for the following: the differences among biological, multidisciplinary, and technological journals
(B-M-T), the impact factor (in log scale), the number of papers (in log scale), the publisher, Open Access, and the age
(in log scale). Analysis of the deviance table from binomial GLM with the LR Chisq, df, p-value, and directionality of
the effect for continuous variables.
Abbreviations: B-M-T, biological, multidisciplinary, and technological journal; df, degrees of freedom; GLM,
generalised linear model; LR Chisq, likelihood ratio chi-squared test
https://doi.org/10.1371/journal.pbio.3000698.t001
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Action to ensure ‘open sequencing data’
Noncompliance with Open Data necessitates failures by the authors, journal managers, editors,
and reviewers. Chronic failures to ensure Open Data should also be prioritised by funders, as
there might be insufficient disincentives for noncompliance. Differences among journal poli-
cies (or lack thereof) and their ability to enforce such policies might explain some of these defi-
ciencies. Technological/applied science journals are a rapidly growing publisher of studies
containing metagenomic data and are currently the least likely publisher to comply with Open
Data. It is clear that the best practice between disciplines is not being shared and that publish-
ers and editors must work towards harmonising metagenomic submission requirements
across disciplines and ensure compliance is obligatory.
On average, between 50 and 90 metagenome-containing articles per year are not available
out of the 300 to 400 papers per year we screened, with an abrupt increase of 50 metagenomes
out of 170 for the first months of 2019. Although the estimates of open metagenomic data
compliance are not inclusive of all studies containing metagenomes, we feel this study does
represent an unbiased survey of the literature. As such, we feel that this study should be used
as a warning of a potentially growing problem, particularly in journals without a tradition of
publishing studies with metagenomes and perhaps without access to the kind of reviewer base
that holds Open Data as a priority.
Data availability reflects on the transparency of the scientific research and its reliability—
compliance is a matter of scientific integrity and should be a requirement for all research that
has public funding. Barriers to compliance with best practice need to be explored to ensure
that complete Open Data is achievable. It should be noted that making data available is only
the first step. Equally essential is the extent and accuracy to which associated metadata are pro-
vided, which are needed to put results into context and inform follow-up studies. Technical
problems might also hamper accessibility to data sets. Of the studies that reported that they
submitted their data to MG-RAST, we were unable to find 34.0%, meaning that one-third of
the reported accession numbers for MG-RAST did not lead to sequence data (29 out of 85 arti-
cles). This happened only for 6.2% of the NCBI/ENA/DDBJ accession numbers (difference:
Chisq1 = 76.7, p< 0.0001). Furthermore, sequencing data was the only data type analysed
here, and the archiving of other types of primary data is much less standardised and common
compared to nucleic acid data [12,13]. For phylogenies, for example, it has been estimated that
60% of the data are not available to science [14]. Guidelines for sequence submission are stan-
dard for most journals, but such standards might not be true for other primary data; an analy-
sis of the guidelines for authors of biomedical journals showed that only 12% of journals
required general data sharing for publications [15]. Furthermore, the analysis presented here
quantifies those studies that reported an accession number or link to sequence data, but it does
not verify the quality of the attached metadata. Dubious metadata might additionally hamper
the usefulness of submitted sequences for others (i.e., specific details of sampling conditions,
location, associated environmental conditions, i.e., aerobic versus anaerobic, healthy or sick
individuals, etc. [16]) and thereby increase the fraction of de facto unavailable metagenomes to
science.
Tax-payer–funded research must be open to the global research community. We acknowl-
edge there are barriers to compliance and all stakeholders need to ensure that these barriers
are quickly and methodically addressed. Publishers without a history of publishing studies
with metagenomic data need to learn the best practices from other publishers with a long and
successful track record of ensuring Open Data. Data accessibility should be an ethical standard
met by all researchers.
PLOS BIOLOGY
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000698 April 3, 2020 5 / 7
Supporting information
S1 Text. Materials and methods.
(DOCX)
S1 Data. List of journals with scientific fields. Fields, IF, publisher, and number of published
papers according to Clarivate Analytics; DOAJ; main group according to the distinction
between biological, multidisciplinary, or technological papers. DOAJ, Directory of Open
Access Journals; IF, impact factor.
(XLSX)
S2 Data. The data set used for the analyses. It contains the 1,269 papers that passed the filter-
ing steps of our literature survey on papers published between 2016 and 2019.
(XLSX)
S1 Fig. Trend of accessibility of metagenomes over time. Data referrals for the year 2016 till
March 2019.
(TIFF)
S2 Fig. Difference in proportion of papers with accessible metagenomic data across scien-
tific fields. Data collected according to Clarivate Web of Science.
(TIFF)
S3 Fig. Differences between the proportion of data accessibility. Data related to the (A) pub-
lisher, (B) journal impact factor, and (C) number of papers published. Trendlines in (B) and
(C) are from the GLMs cited in Table 1.
(TIFF)
S4 Fig. Graphical depiction of multicollinearity between predictors used for statistical models.
(TIFF)
Acknowledgments
We thank all of the colleagues who made their metagenomic data available for the published
papers we screened. NEREUS COST Action ES1403 (http://www.nereus-cost.eu), DNAqua-
net COST Action CA15219 (http://dnaqua.net), and the association Microb&co (https://www.
microbeco.org/) for the promotion of microbial ecology are acknowledged for offering space
for discussion and brainstorming between the authors.
Ethics Statement: No animals nor human participants were involved in the production
and analysis of the data used for this article.
References
1. Schiltz M. Science without publication paywalls: cOAlition S for the realisation of full and immediate
Open Access. PLoS Med 15(9), e1002663 (2018). https://doi.org/10.1371/journal.pmed.1002663
PMID: 30178782
2. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR Guiding
Principles for scientific data management and stewardship. Sci Data 3, 160018 (2016). https://doi.org/
10.1038/sdata.2016.18 PMID: 26978244
3. Mitchell AL, Scheremetjew M, Denise H, Potter S, Tarkowska A, Qureshi M, et al. EBI Metagenomics in
2017: enriching the analysis of microbial communities, from sequence reads to assemblies. Nucleic
Acids Res 4(46), D726–D735 (2018).
4. Albertsen M, Hugenholtz P, Skarshewski A, Nielsen KL, Tyson GW, Nielsen PH. Genome sequences
of rare, uncultured bacteria obtained by differential coverage binning of multiple metagenomes. Nat Bio-
technol 31(6), 533–538 (2013). https://doi.org/10.1038/nbt.2579 PMID: 23707974
PLOS BIOLOGY
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000698 April 3, 2020 6 / 7
5. Burstein D, Harrington LB, Strutt SC, Probst AJ, Anantharaman K, Thomas BC, et al. New CRISPR–
Cas systems from uncultivated microbes. Nature 542(7640), 237–241 (2017). https://doi.org/10.1038/
nature21059 PMID: 28005056
6. Lozupone CA. Unravelling Interactions between the Microbiome and the Host Immune System To Deci-
pher Mechanisms of Disease. mSystems 3(2), e00183–17 (2018). https://doi.org/10.1128/mSystems.
00183-17 PMID: 29556546
7. Huijboom N, Van den Broek T, Open data: an international comparison of strategies. European Journal
of ePractice 12(1), 4–16 (2011).
8. Treasury HM. Putting the frontline first: smarter government. Cm 7753, 22–25 (2009).
9. Borges V, Pinheiro M, Pechirra P, Guiomar R, Gomes JP. INSaFLU: an automated open web-based
bioinformatics suite “from-reads” for influenza whole-genome-sequencing-based surveillance. Genome
Med 10(1), 46 (2018). https://doi.org/10.1186/s13073-018-0555-0 PMID: 29954441
10. Heymann DL. Data sharing and outbreaks: best practice exemplified. Lancet https://doi.org/10.1016/
S0140-6736(20)30184-7 (2020)
11. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat
Med, https://doi.org/10.1038/s41591-020-0820-9 (2020).
12. Starr J, Castro E, Crosas M, Dumontier M, Downs RR, Duerr R, et al. Achieving human and machine
accessibility of cited data in scholarly publications. PeerJ Comput Sci 1, e1 (2015). https://doi.org/10.
7717/peerj-cs.1 PMID: 26167542
13. Groth P, Cousijn H, Clark T, Goble G. FAIR data reuse–the path through data citation. Data Intelligence,
78–86 (2020).
14. Magee AF, May MR, Moore BR. The dawn of open access to phylogenetic data. PLoS ONE 9(10),
e110268 (2014). https://doi.org/10.1371/journal.pone.0110268 PMID: 25343725
15. Vasilevsky NA, Minnier J, Haendel MA, Champieux RE. Reproducible and reusable research: are jour-
nal data sharing policies meeting the mark? PeerJ 5, e3208 (2017). https://doi.org/10.7717/peerj.3208
PMID: 28462024
16. Pope LC, Liggins L, Keyse J, Carvalho SB, Riginos C. Not the time or the place: the missing spatio-tem-
poral link in publicly available genetic data. Mol Ecol 24, 3802–3809 (2015). https://doi.org/10.1111/
mec.13254 PMID: 26033415
PLOS BIOLOGY
PLOS Biology | https://doi.org/10.1371/journal.pbio.3000698 April 3, 2020 7 / 7
